Abstract
Optimized production, quality control and preclinical evaluation of 68Ga-PSMA-617 as a PET radiotracer for PSMA-positive malignancies as well as successful application in imaging of breast adenocarcinomas are reported. 68Ga-PSMA-617 radiolabeling and QC optimization, stability, log P, biodistribution in breast adenocarcinomas-bearing mice (direct and blockade studies) and also PET/CT imaging was performed. 68Ga-PSMA-617 complex was prepared in high radiochemical purity (>96%, ITLC, HPLC) and specific activity of 300–310 GBq/mM at 95 °C using 2–4 micrograms of the peptide in 10 min followed by solid phase purification. The tracer was stable in serum and final formulation for at least 120 min. The log P was −1.98. Western blot test on the tumor cell homogenates demonstrated distinct existence of the PSMA on the surface. The biodistribution of the tracer demonstrated specific kidney and tumor significant uptake using blocking study. Significant tumor:blood and tumor:muscle ratio uptake observed at 30 min post-injection (2.69 and 19.1, respectively). A reduction of 40–80% off tumor uptake in the study time period observed using blocking test. 68Ga-PSMA-617 can be proposing a possible tracer for PET imaging of breast adenocarcinomas and other breast malignancies.
Acknowledgments
We acknowledge the financial support of Iran National Science Foundation (INSF) for conducting this research project for development of Ga-68 labeled peptides (Under 93035935).
References
1. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., Bray, F.: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), E359 (2015).10.1002/ijc.29210Search in Google Scholar
2. Robinson, M. B., Blakely, R., Couto, R., Coyle, J.: Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J. Biol. Chem. 262(30), 14498 (1987).10.1016/S0021-9258(18)47823-4Search in Google Scholar
3. Benešová, M., Schäfer, M., Bauder-Wüst, U., Afshar-Oromieh, A., Kratochwil, C., Mier, W., Haberkorn, U., Kopka, C., Eder, M.: Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J. Nucl. Med. 114, 147 (2015).10.2967/jnumed.114.147413Search in Google Scholar PubMed
4. Kratochwil, C., Giesel, F. L., Eder, M., Afshar-Oromieh, A., Benešová, M., Mier, W., Kopka, K., Haberkorn, U.: [177Lu] Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur. J. Nucl. Med. Mol. Imag. 42(6), 987 (2015).10.1007/s00259-014-2978-1Search in Google Scholar PubMed
5. Table of Isotopes, 2 Volume Set, by Richard B Firestone, Virginia S Shirley (Editor), pp 3168 ISBN 0-471-33056-6 Wiley-VCH, December 1998;1.Search in Google Scholar
6. Shanehsazzadeh, S., Yousefnia, H., Jalilian, A. R., Zolghadri, S., Lahooti, A.: Estimated human absorbed dose for 68Ga-ECC based on mice data: comparison with 67Ga-ECC. Ann. Nucl. Med. 29(6), 475 (2015).10.1007/s12149-015-0967-5Search in Google Scholar PubMed
7. Zhu, H., Xie, Q., Li, N., Tian, H., Liu, F., Yang, Z.: Radio-synthesis and mass spectrometry analysis of 68Ga-DKFZ-PSMA-617 for non-invasive prostate cancer PET imaging. J. Radioanal. Nucl. Chem. 309(2), 575 (2016).10.1007/s10967-015-4623-2Search in Google Scholar
8. Verburg, F. A., Krohn, T., Heinzel, A., Mottaghy, F. M., Behrendt, F. F.: First evidence of PSMA expression in differentiated thyroid cancer using [68Ga] PSMA-HBED-CC PET/CT. Eur. J. Nucl. Med. Mol. Imag. 42(10), 1622 (2015).10.1007/s00259-015-3065-ySearch in Google Scholar PubMed
9. Nass, S. J., Henderson, I. C., Lashof, J. C. (eds.): Mammography and Beyond: Developing Technologies for Early Detection of Breast Cancer. Washington, DC: National Academy Press, 2001. 316 pp. ISBN 0-309-07283-2.Search in Google Scholar
10. Mirzaie, A., Jalilian, A. R., Badbarin, A., Geramifar, P., Beiki, D.: Optimized production and quality control of 68Ga-EDTMP for small clinical trials. Ann. Nucl. Med. 29, 506 (2015).10.1007/s12149-015-0971-9Search in Google Scholar PubMed
11. Zoghi, M., Niazi, A., Jalilian, A. R., Johari-daha, F., Alireapour, B., Ramezanpour, S.: Development of a Ga-68 labeled triptorelin analog for GnRH receptor imaging. Radiochim. Acta 104, 247 (2015).10.1515/ract-2015-2443Search in Google Scholar
12. Alirezapour, B., Rasaee, M. J., Jalilian, A. R., Rajabifar, S., Mohammadnejad, J., Paknejad, M., Maadi, E., Moradkhani, S.: Development of [64Cu]-DOTA-PR81 radioimmunoconjugate for MUC-1 positive PET imaging. Nucl. Med. Biol. 43(1), 73 (2016).10.1016/j.nucmedbio.2015.07.012Search in Google Scholar PubMed
13. Pettersson, K., Piironen, T., Seppälä, M., Liukkonen, L., Christensson, A., Matikainen, M. T., Suonpää, M., Lövgren, T., Lilja, H.: Free and complexed prostate-specific antigen (PSA) – in-vitro stability, epitope map, and development of immunofluorimetric assays for specific and sensitive detection of free PSA and PSA-alpha(1)-antichymotrypsin complex. Clin. Chem. 41, 1480 (1995).10.1093/clinchem/41.10.1480Search in Google Scholar
14. Mirzaei, A., Jalilian, A. R., Aghanejad, A., Mazidi, M., Yousefnia, H., Shabani, G., Ardaneh, K., Geramifar, P., Beiki, D.: Preparation and evaluation of 68Ga-ECC as a PET renal imaging agent. Nucl. Med. Mol. Imaging 49, 208 (2015).10.1007/s13139-015-0323-7Search in Google Scholar PubMed PubMed Central
15. Breeman, W. A., de Jong, M., de Blois, E., Bernard, B. F., Konijnenberg, M., Krenning, E. P.: Radiolabeling DOTA-peptides with 68Ga. Eur. J. Nucl. Med. Mol. Imag. 32, 478 (2005).10.1007/s00259-004-1702-ySearch in Google Scholar PubMed
16. Chang, S. S.: Overview of prostate-specific membrane antigen. Rev. Urol. 6(Suppl 10), S13 (2004).Search in Google Scholar
17. Végvári, A., Rezeli, M., Welinder, C., Malm, J., Lilja, H., Marko-Varga, G., Laurell, T.: Identification of prostate specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms. J. Proteomics. 73(6), 1137 (2010).10.1016/j.jprot.2010.01.008Search in Google Scholar PubMed PubMed Central
18. Silver, D. A., Pellicer, I., Fair, W. R., Heston, W. D., Cordon-Cardo, C.: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3(1), 81 (1997).Search in Google Scholar
19. Liu, T., Jabbes, M., Nedrow-Byers, J. R., Wu, L. Y., Bryan, J. N., Berkman, C. E.: Detection of prostate-specific membrane antigen on HUVECs in response to breast tumor-conditioned medium. Int. J. Oncol. 38(5), 1349 (2011).10.3892/ijo.2011.946Search in Google Scholar PubMed
20. Nomura, N., Pastorino, S., Jiang, P., Lambert, G., Crawford, J. R., Gymnopoulos, M., Piccioni, D., Juarez, T., Pingle, S. C., Makale, M., Kesari, S.: Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int. 14(1), 26 (2014). doi: 10.1186/1475-2867-14-26.10.1186/1475-2867-14-26Search in Google Scholar PubMed PubMed Central
21. Sathekge, M., Modiselle, M., Vorster, M., Mokgoro, N., Nyakale, N., Mokaleng, B., Ebenhan, T.: 68Ga-PSMA imaging of metastatic breast cancer. Eur. J. Nucl. Med. Mol. Imaging. 42(9), 1482 (2015).10.1007/s00259-015-3066-xSearch in Google Scholar PubMed
22. Kinoshita, Y., Kuratsukuri, K., Landas, S., Imaida, K., Rovito, P. M. Jr., Wang, C. Y., Haas, G. P.: Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J. Surg. 30, 628 (2006).10.1007/s00268-005-0544-5Search in Google Scholar PubMed
23. Evans, J. C., Malhotra, M., Cryan, J. F., O’Driscoll, C. M.: The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease. Br. J. Pharmacol. 173(21), 3041 (2016).10.1111/bph.13576Search in Google Scholar PubMed PubMed Central
24. Wernicke, A. G., Varma, S., Greenwood, E. A., Christos, P. J., Chao, K. S., Liu, H., Bander, N. H., Shin, S. J.: Prostate- specific membrane antigen expression in tumor-associated vasculature of breast cancers. APMIS. 122(6), 482 (2014).10.1111/apm.12195Search in Google Scholar PubMed
©2017 Walter de Gruyter GmbH, Berlin/Boston